Table 6.

Studies evaluating maternal BMI as a determinant of maternal or neonatal PFAS concentrations by PFAS, study design, and findings

PFAS (study design) a	N	Positive findings	N	Negative findings	N	Null findings
Legacy PFAS
PFOA (C/L)	–	–	–	–	8	[42, 61, 62, 65, 78, 81, 82, 88]
PFOA (C-S)	1	[89]	2	[91, 93]	9	[66, 67, 72, 74, 83, 86, 87, 92, 94]
PFOS (C/L)	2	[78, 88]	1	[42]	5	[61, 62, 65, 81, 82]
PFOS (C-S)	1	[89]	4	[67, 74, 83, 91]	7	[66, 72, 86, 87, 92–94]
PFNA (C/L)	–	–	3	[42, 78, 82]	2	[65, 81]
PFNA (C-S)	1	[86]	1	[94]	7	[66, 74, 83, 87, 89, 91, 93]
PFHxS (C/L)	–	–	–	–	8	[42, 61, 62, 65, 78, 81, 82, 88]
PFHxS (C-S)	2	[66, 89]	2	[74, 87]	5	[83, 86, 91, 93, 94]
Other PFAS
Et-PFOSA-AcOH (C/L)	1	[78]	–	–	–	–
Me-PFOSA-AcOH (C/L)	1	[78]	–	–	1	[42]
NMeFOSAA (C-S)	–	–	–	–	1	[74]
PFDeA (C/L)	–	–	2	[65, 82]	–	–
PFDeA (C-S)	1	[86]	1	[93]	2	[74, 87]
PFDoA (C/L)	–	–	1	[82]	1	[88]
PFDoA (C-S)	1	[86]	–	–	1	[87]
PFHpA (C-S)	1	[86]	–	–	–	–
PFHpS (C/L)	–	–	–	–	1	[65]
PFHpS (C-S)	–	–	–	–	1	[93]
PFOSA (C-S)	–	–	–	–	1	[86]
PFPeA (C-S)	–	–	–	–	1	[74]
PFTrDA (C/L)	–	–	1	[82]	–	–
PFTrDA (C-S)	–	–	–	–	1	[87]
PFUnDA (C/L)	–	–	1	[65]	2	[82, 88]
PFUnDA (C-S)	–	–	2	[74, 93]	3	[86, 87, 89]
6:2 Cl-PFESA (C/L)	–	–	1	[88]	–	–
ΣPFAS (C-S)	–	–	–	–	1	[87]

^a C/L Cohort/longitudinal studies, C-S Cross-sectional studies, PFOA Perfluorooctanoic acid, PFOS Perfluorooctane sulfonic acid, PFNA Perfluorononanoic acid, PFHxS Perfluorohexane sulfonate, Et-PFOSA-AcOH 2-(N-Ethyl-perfluorooctane sulfonamido) acetic acid, Me-PFOSA-AcOH 2-(N-Methyl-perfluorooctane sulfonamido) acetic acid, NMeFOSAA N-methyl perfluorooctanesulfonamidoacetic acid, PFDeA Perfluorodecanoic acid, PFDoA Perfluorododecanoic acid, PFHpA Perfluoroheptanoic acid, PFHpS Perfluoroheptanesulfonic acid, PFOSA Perfluorooctanesulfonamide, PFPeA Perfluoropentanoic acid, PFTrDA Perfluorotridecanoic acid, PFUnDA Perfluoroundecanoic acid, 6:2 Cl-PFESA Chlorinated polyfluorinated ether sulfonate